04-18-05

Attorney's Docket No.: 17111-009001 / 2309

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Hubert Köster, Ph.D. et al.	Art Unit	: 1639
Serial No.	: 10/760,085	Examiner	: Jon D. Epperson
Filed	: January 16, 2004	Cust. No.	: 20985
Conf. No.	: 8019		
Title	: CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS		

Mail Stop PGPUBt
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:

Transmitted herewith are a Request for Corrected Publication in Accordance with 37 C.F.R. §1.221(b) (3 pages), Hand-Annotated Sheets (10 pages), and a return postcard for filing in connection with the above-identified application.

☒ The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,

Stephanie Seidman
Reg. No. 33,779

Attorney Docket No. 17111-009001/2309
Address all correspondence to:
Stephanie L. Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-5070
Facsimile: (202) 626-7796
email: seidman@fr.com

CERTIFICATE OF MAILING BY "EXPRESS MAIL"
"Express Mail" Mailing Label Number EV 471532207 US
Date of Deposit April 15, 2005
I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie Seidman

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Hubert Köster, Ph.D. et al.	Art Unit	: 1639
Serial No.	: 10/760,085	Examiner	: Jon D. Epperson
Filed	: January 16, 2004	Cust. No.	: 20985
Conf. No.	: 8019		
Title	: CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS		

Mail Stop PGPUB
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED PUBLICATION IN ACCORDANCE WITH 37 C.F.R. §1.221(b)

Applicant hereby requests a Corrected Publication pursuant to 37 C.F.R. §§ 1.221(b). The above-identified application, which published as US-2005-0042771-A1 on February 24, 2005, contained the following material errors that were created by the USPTO:

On page 32:

The fourth structure shown on page 32 of the publication was incorrectly printed by the PTO. The bond indicated on the marked up copy of page 32 should be a "dashed" bond instead of the "wedged" bond shown. This is supported in the application as filed on page 93.

On page 33:

The second and third structures shown on page 33 of the publication were incorrectly printed by the PTO. For both structures, the bond indicated on the marked up copy of page 33 should be a "dashed" bond instead of the "wedged" bond shown. This is supported in the application as filed on page 93.

On page 34:

The first and third structures shown on page 34 of the publication were incorrectly printed by the PTO. For both structures, the bond indicated on the marked up copy of page

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number **EV 471532207 US**
Date of Deposit **April 15, 2005**
I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie L. Seidman

34 copy should be a "dashed" bond instead of the "wedged" bond shown. This is supported in the application as filed on page 94.

On page 35:

The first structure shown on page 35 of the publication was incorrectly printed by the PTO. The bond indicated on the marked up copy of page 35 copy should be a "dashed" bond instead of the "wedged" bond shown. This is supported in the application as filed on page 94.

On page 53:

Two of the structures shown on page 53 of the publication were incorrectly printed by the PTO. The structures should have Nitrogen (N) only instead of NH, as indicated on the mark up copy of page 53. This is supported in the application as filed on page 130.

Also, the reaction shown on page 53 of the publication was incorrectly printed by the PTO. The reaction as indicated on the marked up copy of 53, shows two intermediate compounds producing the end compound. The reaction should flow to Biocytin and then from Biocytin to the end compound. This is supported in the application as filed on pages 130-131.

On page 82:

The structure at the bottom of this page was incorrectly printed by the PTO. The publication incorrectly shows a break in the bond at the lower portion of the structure as indicated on the marked up copy of page 82. There is no break in this structure. This is supported in the application as filed on page 205.

On page 83:

The structure at the top of this page was incorrectly printed by the PTO. The publication incorrectly shows a break in the bond at the lower portion of the structure as indicated on the marked up copy of page 83. There is no break in this structure. This is supported in the application as filed on page 205.

On page 84:

The structure on this page, was incorrectly printed by the PTO. The publication incorrectly shows a break in the bond at the lower portion of the structure as indicated on the marked up copy of page 84. There is no break in this structure. This is supported in the application as filed on page 207.

On page 85:

The structure on this page, was incorrectly printed by the PTO. The publication incorrectly shows a break in the bond at the lower portion of the structure as indicated on the marked up copy of page 85. There is no break in this structure. This is supported in the application as filed on page 207.

On page 86:

The structure on this page, was incorrectly printed by the PTO. The publication incorrectly shows a break in the bond at the lower portion of the structure as indicated on the marked up copy of page 86. There is no break in this structure. This is supported in the application as filed on page 208.

REMARKS

This Request for Corrected Publication seeks to correct material errors to the chemical structures introduced by the Patent and Trademark Office for publication. It is believed these errors are material as apparent from the application as filed. Applicant respectfully requests correction of these material errors by issuance of a corrected publication.

It is believed no fee is due. However, if it is determined that a fee is due, the Office is hereby authorized to charge the fee to Deposit Account No. 06-1050.

Respectfully submitted,

Stephanie Seidman
Reg. No. 33,779

Attorney Docket No. 17111-009001 / 2309
Address all correspondence to:
Stephanie L. Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-5070
Facsimile: (202) 626-7796
email: seidman@fr.com

[0362] In other embodiments, the drug is CELEBREX® (celecoxib) and the capture compounds have the formulae:



-continued



-continued



-continued



[0363] In another embodiment, the drug is VIOXX® (rofecoxib) and the capture compounds have the formulae:





-continued


CO2Me
CHO
CF3SiMe
CHOH
F3C
Dess-Martin
periodinane
O
NOH
1) LiOH/
H2O/MeOH
2) TsCl
NOTs
anhyd. NH3
NH
CO2H
I2 or Ag2O
DCC/NHS/DMF
NHS, DIC
Biotin
Lysine/Et3N/
50 mM
NaHCO3
Biocytin
1) 2
2) DMF
1/
BOBt
DCC
/DMF
SO2NH2

[0826] Rezulin is metabolized in the liver to its p-Hydroxy glucose and sulfate complexes. Therefore Structure II is considered.

[0827] Rezulin Capture Compound Structures I and II are incubated with kidney, liver, pancreatic, colon epithelium, and muscle cells. The target protein PPAR-γ as well as non-target protein PPAR-α and protein A, B and C are captured.

[0828] Avandia and Its Metabolite:

[0829] Avandia is attached to the capture compound as depicted below:



[0830] Avandia metabolizes to aromatic hydroxy metabolites. Therefore two possible metabolites are attached to the capture compound as depicted below:



-continued

Metabolite

Metabolite

Metabolite

[0831] Avandia and its metabolites attached to the Capture Compound are incubated with kidney, liver, pancreatic, colon epithelium, and muscle cells. The target protein PPAR-γ as well as non-target protein PPAR-α and protein A, B and C are captured.

[0832] Actos and Its Metabolites:

[0833] Actos is attached to the Capture Compound as depicted below:



-continued



[0834] Actos' possible metabolite is attached to the capture compound as depicted below: